FDA clears four cancer drugs in two weeks, including new ALK and ESR1-mutant options
Between Nov 7 and 21, 2026, the FDA approved neladalkib, giredestrant plus everolimus, durvalumab with enfortumab vedotin, and a pertuzumab biosimilar.
Summary
In the two weeks from November 7 to 21, 2026, the FDA approved four cancer-related products. Neladalkib (Nelkarmi) received accelerated approval for adults with previously treated ALK-positive non-small cell lung cancer. Giredestrant (Wilserdly) was approved with everolimus for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. Durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) was approved as neoadjuvant therapy, followed by adjuvant durvalumab, for muscle-invasive bladder cancer in people who cannot or will not take cisplatin. Pebrilzo, a pertuzumab biosimilar, was approved for HER2-positive breast cancer. The source is a news-archive listing with approval dates and indications only. It does not report efficacy, survival or safety data, so what these drugs deliver in practice cannot be judged from it. Because cancer risk rises steeply with age, new options matter for older adults.
Detailed Summary
Cancer incidence climbs steeply with age, so new approvals in lung, breast and bladder cancer bear directly on healthspan in older adults. This listing records four FDA actions in a two-week window, November 7 to 21, 2026.
The first is neladalkib (Nelkarmi), approved November 17 under accelerated approval for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. Eligible patients previously received one ALK inhibitor including alectinib, or at least two ALK inhibitors plus platinum chemotherapy. The second is giredestrant (Wilserdly), approved November 16 with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after endocrine therapy recurrence or progression.
Third, durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) was approved November 13 as neoadjuvant treatment, followed by adjuvant durvalumab after radical cystectomy, for muscle-invasive bladder cancer in adults ineligible for or declining cisplatin-based chemotherapy. Fourth, Pebrilzo (pertuzumab-qcay), a pertuzumab biosimilar, was approved November 12 for existing HER2-positive breast cancer indications. The source notes that giredestrant and neladalkib appear on the FDA's novel-drug list, while the combination and the biosimilar are counted as cancer-related approvals rather than novel drugs.
The mechanistic theme is biomarker-matched therapy: an ALK alteration, an ESR1 mutation, and HER2 status each define who is eligible. The bladder regimen offers a perioperative option for people who cannot receive cisplatin, who are often older. The biosimilar may widen access to an established HER2-directed agent.
Caveats are substantial. The source supplies no trial data, response rates, survival, or adverse events. Accelerated approval for neladalkib typically rests on surrogate endpoints such as response rate, and confirmatory evidence is still required. Anyone considering these drugs should discuss eligibility, benefit and risks with an oncologist. This summary rests on a brief listing, not full prescribing information.
Key Findings
- Neladalkib (Nelkarmi) received accelerated approval Nov 17, 2026 for previously treated ALK-positive metastatic non-small cell lung cancer.
- Giredestrant (Wilserdly) plus everolimus was approved Nov 16 for ER+/HER2-, ESR1-mutated advanced breast cancer after endocrine therapy.
- Durvalumab plus enfortumab vedotin was approved Nov 13 for cisplatin-ineligible muscle-invasive bladder cancer, given before and after cystectomy.
- Pebrilzo, a pertuzumab biosimilar, was approved Nov 12 for HER2-positive breast cancer; no efficacy or safety data appear in the source.
Methodology
This is a regulatory news listing, not a study. It tabulates drug names, indications and approval dates for FDA cancer approvals from Nov 7 to 21, 2026, cross-referencing the FDA novel-drug list. No trial design, sample sizes or endpoints are reported.
Study Limitations
The summary is based on the abstract only, a brief listing without efficacy, survival, safety or trial data. Accelerated approval implies confirmatory evidence is still pending for neladalkib. The listing does not establish clinical benefit magnitude, and no mechanism, function or lifespan outcomes are reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
